MASON, Ohio--(BUSINESS WIRE)--Nov. 11, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
Sven Wehrwein has been appointed to its Board of Directors.
Mr. Wehrwein has been an independent financial consultant to emerging
companies since 1999. He has more than 35 years of experience as an
investment banker, chief financial officer, and certified public
accountant. Wehrwein currently sits on the boards of several companies,
including Proto Labs, Inc. and SPS Commerce, Inc. In addition, he has
served as a Director for a number of other medical device and high
growth companies including tenures on the boards of Compellent
Technologies, Synovis Life Technologies, and Vital Images.
“Sven has a wealth of experience that will be beneficial to the
company,” said Mike Carrel, President and CEO of AtriCure. “He brings a
deep level of expertise in corporate finance, accounting and strategy,
and has been on the Boards of numerous successful public companies. We
are fortunate to have him on our Board.”
“I am pleased to be joining the AtriCure Board,” added Wehrwein. “It is
an exciting time for the company, which is well positioned to continue
being a leader in the Afib and LAA markets. I look forward to doing my
part to help guide continued growth.”
About AtriCure
AtriCure, Inc. is a medical device company that provides innovative
solutions designed to decrease the global Afib epidemic. AtriCure’s
Isolator® Synergy™ Ablation System is the first and only surgical device
approved for the treatment of persistent and longstanding persistent
forms of Afib in patients undergoing certain open concomitant
procedures. AtriCure’s AtriClip® Left Atrial Appendage Management (LAAM)
exclusion device is the most widely sold device worldwide that is
indicated for the occlusion of the left atrial appendage. AtriCure
believes electrophysiologists and cardiothoracic surgeons are adopting
its technologies for the treatment of Afib and reduction of Afib related
complications. Afib affects more than 33 million people worldwide. For
more information, visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161111005022/en/
Source: AtriCure, Inc.
AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President
and Chief Financial Officer
awade@AtriCure.com
or
Investor
Relations Contact
Gilmartin Group
Lynn Pieper Lewis,
415-937-5402
lynn@gilmartinir.com
